분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-12-10 14:09:41 , Hit : 1890
 128781_web1961461707.jpg (59.1 KB), Download : 6
 Anti-CRISPR Protein Is Gene Editing “Off-Switch”


GEN News Highlights
December 9, 2016

This visual abstract depicts the finding that naturally occurring inhibitors of CRISPR-Cas9 can block genome editing in cultured human cells, providing a means to spatially, temporally, and conditionally control Cas9 activity. [Pawluk et al./Cell 2016]

Scientists at the UMass Medical School and the University of Toronto say they have discovered the first known "off-switches" for CRISPR/Cas9 activity, providing much greater control over the edits, according to a new study ("Naturally Occurring Off-Switches for CRISPR-Cas9") published in Cell.

Erik J. Sontheimer, Ph.D., professor in the RNA Therapeutics Institute at UMass Medical School, along with Alan Davidson, Ph.D., professor of molecular genetics, and Karen Maxwell, Ph.D., assistant professor of biochemistry, at the University of Toronto, identified three naturally occurring proteins that inhibit the Cas9 enzyme. These proteins, known as anti-CRISPRs, have the ability to block DNA cleavage by the Cas9 nuclease.

"CRISPR/Cas9 is a good thing because it introduces specific chromosome breaks that can be exploited to create genome edits, but because chromosome breakage can be hazardous, it is possible to have too much of a good thing, or to have it go on for too long," Dr. Sontheimer said. "There is a current shortage of reliable ways to turn off Cas9 once it has already been delivered to a cell. If you can trip an off-switch after the correct editing is done, then the problem is relieved. We report the first known natural inhibitors of Cas9 activity."

"CRISPR is very powerful, but we have to be able to turn it off," Dr. Davidson added. "This is a very fundamental addition to the toolbox, which should give researchers more confidence to use gene editing."

Despite the power of the CRISPR/Cas9 system, it isn't exact. There are times when the RNA guide used to maneuver the cleaving enzyme into the right position within the genome also targets the enzyme to other sequences that are similar but not identical. These mismatched sites, which can occur as many as 100 times across the 6 billion nucleotides that make up the human genome, can sometimes also be cleaved, causing unintended damage.

In many CRISPR/Cas9 applications—including those under therapeutic development—there is a specific cell type, tissue, or organ that is being targeted for editing, as that is where the disease manifests itself, or where the therapeutic benefit can be realized.

"CRISPR/Cas9 might go to the intended cells in these cases, but it will also likely go to other ancillary cells, tissues, or organs as well. Cas9 activity in these ancillary cells, tissues, or organs is at best useless and at worst a safety risk," Dr. Sontheimer said. "But if you could build an off-switch that keeps Cas9 inactive everywhere except the intended target tissue, then the tissue specificity will be improved."

The new paper not only identifies that "off-switch," he explained, but it shows that Cas9 inhibitors exist naturally and can be identified and exploited.

"There are many different forms of Cas9 that are produced by different bacteria, and the different Cas9s can each have different useful properties in genome editing," continued Dr. Sontheimer. "So there are already several Cas9s in the toolbox, with many more to come. We've now proven that such inhibitors are out there in the natural world and we've provided one possible strategy to find them."







987   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1073
986   Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9  이성욱 2017/02/09 1328
985   유전자 치료로 청력 되살린다  이성욱 2017/02/08 1350
984   바이러스들도 서로 소통..“상황에 따라 감염방식 결정”  이성욱 2017/01/24 1134
983   Oligonucleotide Therapeutics Near Approval  이성욱 2017/01/10 1168
982   Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 994
981   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 821
980   RNA Modification Helps Drosophila Straighten Up and Fly Right  이성욱 2016/12/10 887
  Anti-CRISPR Protein Is Gene Editing “Off-Switch”  이성욱 2016/12/10 1890
978   Could Gene Therapy Work for Alzheimer’s Disease?  이성욱 2016/10/12 1158
977   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1147
976   DNA Can Be Edited Without Being Cut  이성욱 2016/08/30 1419
975   Using RNA to Amplify RNA  이성욱 2016/08/16 1031
974   CRISPR: No Cutting Required  이성욱 2016/08/06 1638
973   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1039
972   Lytic and latent viral replication prevented with CRISPR/Cas9  이성욱 2016/07/27 919
971   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1095
970   FDA OKs AbbVie's once-daily Viekira XR for HCV-1  이성욱 2016/07/27 908
969   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1105
968   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 988

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN